GlassScriptPhysician profile
Greg Matthew Pavich
NPI 1053359216
$1,458.73
in general payments reported to CMS, 2019-2025
20 companies · $170 in 2025
The $170 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $181 · 2021: $288 · 2022: $178 · 2023: $336 · 2024: $187 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $692.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $272.87 | 2022-2025 | Azstarys |
| Tris Pharma INC | $195.89 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $162.81 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $120.55 | 2021-2025 | Qelbree, Qelbree |
| Pfizer INC. | $107.54 | 2020-2025 | |
| Cranial Technologies, INC | $96.75 | 2019-2024 | Doc Band |
| Sobi, INC | $73.31 | 2019-2023 | |
| Quidel Corporation | $51.30 | 2021 | |
| Adlon Therapeutics L.P. | $48.45 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $46.32 | 2021-2025 | Vaxneuvance, Gardasil 9, M-M-R II |
| Biomarin Pharmaceutical INC. | $43.66 | 2022-2025 | Voxzogo 1.2mg |
| Acadia Pharmaceuticals INC | $42.95 | 2023 | Daybue |
| Collegium Pharmaceutical, INC. | $40.45 | 2025 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $40.10 | 2023-2024 | |
| Neuronetics, INC. | $39.76 | 2024 | Neurostar Tms Therapy System |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $22.17 | 2019 | |
| Seqirus USA INC | $17.58 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $13.50 | 2024 | Baqsimi |
| Takeda Pharmaceuticals U.S.A., INC. | $11.45 | 2020 | |
| Qiagen, LLC | $11.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Pavich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.